Suppr超能文献

一级预防中的生物标志物:基于生物标志物评分的有意义诊断?

Biomarkers in primary prevention : Meaningful diagnosis based on biomarker scores?

作者信息

Schulte Christian, Zeller Tanja

机构信息

Klinik für Kardiologie, Universitäres Herz- und Gefäßzentrum Hamburg, Martinistraße 52, 20246, Hamburg, Germany.

Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Standort Hamburg/Lübeck/Kiel, Hamburg, Germany.

出版信息

Herz. 2020 Feb;45(1):10-16. doi: 10.1007/s00059-019-04874-2.

Abstract

Cardiovascular (CV) risk assessment is based on the utilization of risk scores, enabling clinicians to estimate an individual's risk to develop CV pathologies and events. Such risk scores comprise classic CV risk factors such as smoking, diabetes, hypertension, and blood cholesterol levels. Recently, other CV biomarkers such as cardiac troponins have been suggested and evaluated as alternative biomarkers not only in the acute diagnostic setting of myocardial infarction, but also as markers for risk stratification in the general population. In this review, we summarize the current knowledge on biomarkers in the field of primary prevention in cardiovascular disease (CVD). Furthermore, we present potential alternative biomarker-based strategies for CV risk assessment. In this respect we provide an outlook on the potential use of genomic variation as well as circulating non-coding RNAs to complement current risk assessment strategies so as to further personalize risk stratification in CVD.

摘要

心血管(CV)风险评估基于风险评分的运用,使临床医生能够估计个体发生心血管病变和事件的风险。此类风险评分包括吸烟、糖尿病、高血压和血液胆固醇水平等经典心血管风险因素。最近,其他心血管生物标志物,如心肌肌钙蛋白,不仅在心肌梗死的急性诊断环境中,而且在普通人群的风险分层中,都被建议并评估为替代生物标志物。在本综述中,我们总结了心血管疾病(CVD)一级预防领域中生物标志物的当前知识。此外,我们提出了基于生物标志物的潜在替代策略用于心血管风险评估。在这方面,我们展望了基因组变异以及循环非编码RNA在补充当前风险评估策略方面的潜在用途,以便进一步实现心血管疾病风险分层的个性化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验